$549 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 83 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | INVESCO QQQ TRput | $48,903,854 | – | 136,500 | +100.0% | 8.91% | – | |
| SEDG | New | SOLAREDGE TECHNOLOGIES INCcall | $6,928,785 | – | 53,500 | +100.0% | 1.26% | – |
| CYTK | New | CYTOKINETICS INC | $6,891,666 | – | 233,933 | +100.0% | 1.26% | – |
| AMD | New | ADVANCED MICRO DEVICES INC | $4,968,262 | – | 48,320 | +100.0% | 0.90% | – |
| FB | New | META PLATFORMS INCcl a | $4,569,196 | – | 15,220 | +100.0% | 0.83% | – |
| New | PROMIS NEUROSCIENCES INC | $3,686,424 | – | 1,834,042 | +100.0% | 0.67% | – | |
| MIRM | New | MIRUM PHARMACEUTICALS INC | $3,611,374 | – | 114,284 | +100.0% | 0.66% | – |
| REPL | New | REPLIMUNE GROUP INC | $3,165,624 | – | 185,016 | +100.0% | 0.58% | – |
| XENE | New | XENON PHARMACEUTICALS INCput | $2,814,784 | – | 82,400 | +100.0% | 0.51% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEWcall | $2,752,000 | – | 100,000 | +100.0% | 0.50% | – |
| PLRX | New | PLIANT THERAPEUTICS INC | $2,707,364 | – | 156,134 | +100.0% | 0.49% | – |
| ICL | New | ICL GROUP LTD | $2,608,500 | – | 470,000 | +100.0% | 0.48% | – |
| CRWD | New | CROWDSTRIKE HLDGS INCcl a | $2,510,700 | – | 15,000 | +100.0% | 0.46% | – |
| CYTK | New | CYTOKINETICS INCcall | $1,914,900 | – | 65,000 | +100.0% | 0.35% | – |
| GOSS | New | GOSSAMER BIO INC | $1,609,443 | – | 1,932,568 | +100.0% | 0.29% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $1,330,839 | – | 38,959 | +100.0% | 0.24% | – |
| New | APOGEE THERAPEUTICS INC | $639,000 | – | 30,000 | +100.0% | 0.12% | – | |
| New | VISTAGEN THERAPEUTICS INC | $524,000 | – | 100,000 | +100.0% | 0.10% | – | |
| CALT | New | CALLIDITAS THERAPEUTICS ABsponsered ads | $216,618 | – | 11,863 | +100.0% | 0.04% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.